Emerald Advisers LLC Sells 8,223 Shares of Integer Holdings Co. (NYSE:ITGR)

Emerald Advisers LLC reduced its stake in shares of Integer Holdings Co. (NYSE:ITGR) by 56.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,450 shares of the medical equipment provider’s stock after selling 8,223 shares during the period. Emerald Advisers LLC’s holdings in Integer were worth $838,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ITGR. Contravisory Investment Management Inc. grew its stake in Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 80 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Integer by 3,688.9% in the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares during the period. GAMMA Investing LLC raised its position in shares of Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 142 shares in the last quarter. Headlands Technologies LLC bought a new stake in Integer during the first quarter valued at $106,000. Finally, Innealta Capital LLC purchased a new position in Integer during the second quarter worth about $110,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ITGR. Truist Financial dropped their price target on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Bank of America boosted their price target on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Piper Sandler restated an “overweight” rating and set a $140.00 price objective (up previously from $125.00) on shares of Integer in a research report on Friday, October 25th. Benchmark upped their target price on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Citigroup raised their price target on Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Stock Up 1.8 %

Shares of NYSE:ITGR opened at $126.45 on Monday. The stock has a market capitalization of $4.24 billion, a P/E ratio of 39.03, a price-to-earnings-growth ratio of 1.78 and a beta of 1.09. The stock’s 50-day moving average price is $128.00 and its 200-day moving average price is $121.38. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. Integer Holdings Co. has a 12-month low of $82.65 and a 12-month high of $133.53.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. The business had revenue of $431.42 million for the quarter, compared to analysts’ expectations of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.27 EPS. On average, equities analysts anticipate that Integer Holdings Co. will post 5.33 earnings per share for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.